ATXN3 WILDTYPE

# Research Brief: ATXN3 Wildtype Q27 Variant ## Pathogenic Mechanisms ATXN3 encodes ataxin-3, a cysteine-type deubiquitinase that plays critical roles in protein quality control and cellular stress responses. The Q27 wildtype variant contains 27 glutamine residues, representing a normal CAG repeat length below the pathogenic threshold of 52-86 repeats that characterize Machado-Joseph disease (SCA3). Recent literature demonstrates that wildtype ATXN3 exhibits distinct phase separation properties compared to pathogenic expanded variants, suggesting that polyglutamine tract length fundamentally alters protein biophysical behavior. The protein's deubiquitinase activity and ATPase binding capacity are essential for normal cellular functions including actin cytoskeleton organization, response to amino acid starvation, and heat stress adaptation. Key protein-protein interactions with VCP, BECN1, and caspases (CASP1, CASP3) implicate ATXN3 in autophagy and apoptotic pathways, which become dysregulated when polyglutamine expansion occurs. Understanding wildtype Q27 function establishes the baseline against which pathogenic mechanisms can be compared. ## Clinical Significance The Q27 wildtype variant represents the normal, non-pathogenic form of ATXN3 and serves as a critical reference point for understanding SCA3 pathogenesis. Collection of baseline data for this normal-range variant is essential for defining the threshold where polyglutamine expansion triggers neurodegeneration. Unlike pathogenic variants (≥52 repeats) that cause progressive cerebellar ataxia, ophthalmoplegia, and pyramidal signs, the Q27 variant maintains normal protein structure and function. This baseline characterization is clinically valuable for developing therapeutic strategies that aim to selectively reduce mutant ATXN3 while preserving wildtype protein function, as complete loss of ATXN3 may have deleterious consequences given its essential roles in protein quality control and stress response pathways. ## Therapeutic Landscape Structural analysis reveals aggregation hotspots at residues 148-152 (aggregation score: 0.56), identifying a potential target region even in wildtype ATXN3. The candidate peptide CP-ATXN3-001 has been computationally designed to target this 148-152 region, which may represent a conserved aggregation-prone segment that becomes pathologically relevant when polyglutamine tracts expand. This therapeutic approach rationally targets a region distinct from the polyglutamine tract itself, potentially offering opportunities to modulate protein aggregation without directly addressing repeat length. Understanding whether this region exhibits differential aggregation propensity between Q27 and expanded variants could inform peptide-based therapeutic strategies that selectively interfere with pathogenic aggregation while sparing normal protein function. ## Research Directions Critical knowledge gaps include determining how the Q27 wildtype variant's phase separation properties differ quantitatively from pathogenic variants, and whether aggregation hotspot regions (148-152) show enhanced aggregation propensity in expanded variants. Future research should establish comprehensive structural and functional baselines for Q27, including post-translational modifications and interactome mapping under various cellular stress conditions. Gene editing approaches that preserve wildtype alleles while targeting expanded repeats warrant investigation. Additionally, validating CP-ATXN3-001's specificity and efficacy in preventing pathogenic aggregation without disrupting normal ATXN3 function represents an actionable therapeutic direction. Understanding genetic modifiers that influence the pathogenic threshold could reveal why some individuals with intermediate repeats remain asymptomatic.